Clinical Trials Logo

Clinical Trial Summary

Inflammatory bowel diseases (IBD), such as ulcerative colitis (UC) and Crohn's disease (CD), are chronic, relapsing and destructive inflammatory disorder of the intestinal wall. A treat-to-target approach with tight monitoring of intestinal inflammatory lesions is recommended to prevent organ damage and impaired quality of life. Because clinical scores and laboratory assessments have shown poor correlation with intestinal inflammation, endoscopic investigation has to be performed frequently as a reference standard. Due to the fact that colonoscopy (CS) is poorly accepted by patients, expensive, time consuming and harbors the risk of complications, new imaging strategies are required to overcome invasive procedures. The aim of this non-interventional prospective cross-sectional observational study is to investigate the feasibility of using intestinal motility quantified by intestinal ultrasound (US) to evaluate disease activity. The outcomes of intestinal motility detected by ultrasound will be compared with endoscopic and histopathological reference standards in adult patients with IBD


Clinical Trial Description

This is a feasibility, observational, cross-sectional, monocentric study on the evaluation of a non-invasive US approach based on the intestinal motility detection for the assessment of activity in IBD. About 100 IBD patients under treatment at the Gastroenterology Department of the San Raffaele Hospital will be enrolled between September 2022 and September 2023. According to the observational nature of the study, all the visits and procedures described below will be performed according to the diagnostic and therapeutic assignment required by clinical practice for the patients under study. The choice of treatment will be made by the referring physicians according to the international ECCO guidelines. Therefore, the choice of assigning the patient to the diagnostic and therapeutic procedures deemed most appropriate for each case is completely independent of the study. IBD patients will be prospectively identified and consecutively recruited. Within 7 days from the colonoscopy, patients will undergo complete clinical assessment. Harvey-Bradshaw Index (HBI) and partial Mayo score (PMS) will be calculated in Crohn's disease and in ulcerative colitis, respectively. Blood and stool samples will be obtained for C-reactive protein (CRP) and fecal calprotectin (FC) measurements. Bowel US will be performed, in a blinded fashion, after 6-8 hour fasting, using an Aloka Arietta 750 with convex (5-1 MHz) and microconvex probes (4-8 MHz), by two expert gastroenterologists of the IBD center. Neither preparation nor contrast will be used. anonymized cineloops of the ileum segment and sigmoid colon in CD and sigmoid colon in UC, will be recorded and sent to an external cloud platform Entrolytics which is a PACS for ultrasound, for the assessment of motility through a specific software. Any treatment will be kept stable in the interval between the two procedures. The informations obtained on the analysis of intestinal motility will not be used for therapeutic purposes on patients who will follow the therapeutic path provided by the ECCO reference guidelines. For this reason motility analysis will not be used for clinical purposes, but for research purposes only. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05719402
Study type Observational
Source IRCCS San Raffaele
Contact Mariangela Allocca
Phone 0226432069
Email allocca.mariangela@hsr.it
Status Recruiting
Phase
Start date December 15, 2022
Completion date November 25, 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04046913 - The ADDapt Diet in Reducing Crohn's Disease Inflammation N/A
Active, not recruiting NCT04989907 - A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Active, not recruiting NCT04990258 - A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
Completed NCT06216223 - Laser Versus Surgery in Anal Diseases in Inflammatory Bowel Patients N/A
Enrolling by invitation NCT06015789 - Self-care in Patients Affected by Inflammatory Bowel Disease and Caregivers' Contribution to Self-care
Recruiting NCT06065995 - StoMakker Mobile Application N/A
Recruiting NCT03282786 - Comparison of Carbon Dioxide (CO2) to Air Insufflation in Colonoscopy in Patients With Inflammatory Bowel Disease N/A
Recruiting NCT06002074 - SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases N/A
Recruiting NCT04960826 - Study of an Environmental Risk Factor in Crohn's Disease
Recruiting NCT05413941 - Internet-based Cognitive Behavioral Therapy in Inflammatory Bowel Disease N/A
Completed NCT03668249 - A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
Completed NCT00721812 - A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686 Phase 1
Recruiting NCT05809999 - IBD Neoplasia Surveillance RCT N/A
Recruiting NCT04138225 - The Ecological Role of Yeasts in the Human Gut
Recruiting NCT04991324 - Cholecalciferol Comedication in IBD - the 5C-study Phase 3
Completed NCT03173144 - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Not yet recruiting NCT05043818 - A Clinical Study on the Screening of Intestinal Biomarkers in IBD Patients With Depression
Recruiting NCT03042091 - Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery Early Phase 1
Completed NCT02874365 - Intestinal Stem Cells Characterization N/A